This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cardiac Shockwave Therapy in Addition to CABG Improves Myocardial Function in Ischemic Heart Failure: The CAST-HF Trial

Thursday, June 27, 2024

Submitted by



Johannes Holfeld, Felix Nägele, Leo Pölzl, Clemens Engler, Michael Graber, Jakob Hirsch, Sophia Schmidt, Agnes Mayr, Felix Troger, Mathias Pamminger, Markus Theurl, Michael Schreinlechner, Nikolay Sappler, Elfriede Ruttmann-Ulmer, Wolfgang Schaden, John P Cooke, Hanno Ulmer, Axel Bauer, Can Gollmann-Tepeköylü, Michael Grimm

This study evaluated the outcomes after the use of cardiac shockwave therapy (SWT) combined with coronary artery bypass surgery (CABG) in patients with reduced left ventricular ejection fraction (LVEF) due to ischemic cardiomyopathy. Patients with LVEF ≤ 40 percent requiring CABG were enrolled in this single-blind, parallel-group, sham-controlled trial. Patients were randomly assigned to undergo direct cardiac SWT or sham treatment in addition to CABG. The primary efficacy endpoint was the improvement in LVEF measured by cardiac magnetic resonance imaging from baseline to 360 days. A total of 63 patients were randomized, 30 patients in the SWT group and 28 patients in the sham group. A greater improvement in LVEF was observed in the SWT group (Δ from baseline to 360 days: SWT 11.3 percent; Sham 6.3 percent, SD 7.4, P = 0.0146). Furthermore, patients in the SWT group significantly improved in the six minute walking test 360 days after randomization. The authors conclude that direct cardiac SWT, in addition to CABG, improves LVEF and physical capacity in patients with ischemic heart failure.

Add comment

Log in or register to post comments